Texas cardiologist Darren McGuire was on the FDA committee that approved Pradaxa. He later disclosed that he received “personal fees from [Pradaxa manufacturer] Boehringer Ingelheim,” paying him between $75,000 and $134,994 over a three-year period. FDA advisory committee member Sanjay Kaul, a medical professor at UCLA and cardiologist at Cedars-Sinai Medical Center, also received payments from Boehringer Ingelheim in 2013 totaling more than $21,000, and $75,000 a year later.
read more